Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413372 · ClinicalTrials.gov registry record · Phase 2
A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT02413372: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT02413372 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 184 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02413372, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).
Primary Outcome
The mean change in percent hepatic fat fraction (%) by MRI from baseline to Week 16 was assessed for each arm. A longitudinal repeated measures analysis was used to analyze the change in hepatic fat fraction (%) at Week 16 from baseline in the treated population who have both a baseline and at least one post-baseline measurement.
Interventions
- DRUG Placebo
- DRUG BMS-986036
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2015-05-08 |
| Est. Completion | 2017-06-19 |
| Phase | Phase 2 |
What the finished NCT02413372 record still lists
NCT02413372 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02413372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02413372 about?
NCT02413372 is a clinical study titled "A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)". The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).
What is the current status of trial NCT02413372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2015-05-08. Estimated completion is 2017-06-19.
What interventions are being tested in trial NCT02413372?
The interventions under investigation include: Placebo (DRUG), BMS-986036 (DRUG).
Who is sponsoring clinical trial NCT02413372?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02413372's enrollment target sits among peer trials
184 360th of 2000 higher than 1,638 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI